515 related articles for article (PubMed ID: 29788127)
1. Herpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention.
Colombel JF
Inflamm Bowel Dis; 2018 Sep; 24(10):2173-2182. PubMed ID: 29788127
[TBL] [Abstract][Full Text] [Related]
2. Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
Winthrop KL; Melmed GY; Vermeire S; Long MD; Chan G; Pedersen RD; Lawendy N; Thorpe AJ; Nduaka CI; Su C
Inflamm Bowel Dis; 2018 Sep; 24(10):2258-2265. PubMed ID: 29850873
[TBL] [Abstract][Full Text] [Related]
3. Herpes zoster and Janus kinase inhibition in rheumatology and gastroenterology patients: managing risk and vaccination.
Galloway J; Raine T; Rivett L; Roberts J; Dews SA; Choy EH
Clin Exp Rheumatol; 2022 Jul; 40(7):1432-1441. PubMed ID: 34874825
[TBL] [Abstract][Full Text] [Related]
4. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
Olivera PA; Lasa JS; Bonovas S; Danese S; Peyrin-Biroulet L
Gastroenterology; 2020 May; 158(6):1554-1573.e12. PubMed ID: 31926171
[TBL] [Abstract][Full Text] [Related]
5. Contribution of a European-Prevalent Variant near CD83 and an East Asian-Prevalent Variant near IL17RB to Herpes Zoster Risk in Tofacitinib Treatment: Results of Genome-Wide Association Study Meta-Analyses.
Bing N; Zhou H; Chen X; Hirose T; Kochi Y; Tsuchida Y; Ishigaki K; Sumitomo S; Fujio K; Zhang B; Valdez H; Vincent MS; Martin D; Clark JD
Arthritis Rheumatol; 2021 Jul; 73(7):1155-1166. PubMed ID: 33455090
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology and safety of tofacitinib in ulcerative colitis.
López-Sanromán A; Esplugues JV; Domènech E
Gastroenterol Hepatol; 2021 Jan; 44(1):39-48. PubMed ID: 32829958
[TBL] [Abstract][Full Text] [Related]
7. Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study.
Calabrese LH; Abud-Mendoza C; Lindsey SM; Lee SH; Tatulych S; Takiya L; Iikuni N; Soma K; Luo Z; Fleischmann R
Arthritis Care Res (Hoboken); 2020 Mar; 72(3):353-359. PubMed ID: 31207152
[TBL] [Abstract][Full Text] [Related]
8. Using Number Needed to Harm to Put the Risk of Herpes Zoster From Tofacitinib in Perspective.
Caldera F; Hayney MS; Cross RK
Inflamm Bowel Dis; 2019 May; 25(6):955-957. PubMed ID: 30605536
[No Abstract] [Full Text] [Related]
9. Risk for Herpes Zoster in Tofacitinib-Treated Rheumatoid Arthritis Patients With and Without Concomitant Methotrexate and Glucocorticoids.
Curtis JR; Xie F; Yang S; Bernatsky S; Chen L; Yun H; Winthrop K
Arthritis Care Res (Hoboken); 2019 Sep; 71(9):1249-1254. PubMed ID: 30295428
[TBL] [Abstract][Full Text] [Related]
10. Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
Winthrop KL; Vermeire S; Long MD; Panés J; Ng SC; Kulisek N; Mundayat R; Lawendy N; Vranic I; Modesto I; Su C; Melmed GY
Inflamm Bowel Dis; 2023 Jan; 29(1):85-96. PubMed ID: 35648151
[TBL] [Abstract][Full Text] [Related]
11. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis.
Bechman K; Subesinghe S; Norton S; Atzeni F; Galli M; Cope AP; Winthrop KL; Galloway JB
Rheumatology (Oxford); 2019 Oct; 58(10):1755-1766. PubMed ID: 30982883
[TBL] [Abstract][Full Text] [Related]
12. Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme.
Winthrop KL; Loftus EV; Baumgart DC; Reinisch W; Nduaka CI; Lawendy N; Chan G; Mundayat R; Friedman GS; Salese L; Thorpe AJ; Su C
J Crohns Colitis; 2021 Jun; 15(6):914-929. PubMed ID: 33245746
[TBL] [Abstract][Full Text] [Related]
13. Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies.
Gialouri CG; Moustafa S; Thomas K; Hadziyannis E; Vassilopoulos D
Rheumatol Int; 2023 Mar; 43(3):421-435. PubMed ID: 36635577
[TBL] [Abstract][Full Text] [Related]
14. [Inhibition of the Janus kinase-signal transducer and activator of transcription is a new treatment modality of rheumatoid arthritis].
Frøling M; Mikkelsen C; Eggertsen PP; Stern M; van de Looij A; Deleuran B
Ugeskr Laeger; 2017 Oct; 179(44):. PubMed ID: 29084618
[TBL] [Abstract][Full Text] [Related]
15. [Relation between disease modifying anti-rheumatic drugs and herpes zoster in rheumatoid arthritis].
Yamaoka K
Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(3):181-9. PubMed ID: 27320933
[TBL] [Abstract][Full Text] [Related]
16. Tofacitinib for the treatment of ulcerative colitis.
Izzo R; Bevivino G; Monteleone G
Expert Opin Investig Drugs; 2016 Aug; 25(8):991-7. PubMed ID: 27177233
[TBL] [Abstract][Full Text] [Related]
17. Real-World Experience with Tofacitinib in IBD at a Tertiary Center.
Weisshof R; Aharoni Golan M; Sossenheimer PH; El Jurdi K; Ollech JE; Pekow J; Cohen RD; Sakuraba A; Dalal S; Rubin DT
Dig Dis Sci; 2019 Jul; 64(7):1945-1951. PubMed ID: 30734234
[TBL] [Abstract][Full Text] [Related]
18. Tofacitinib in ulcerative colitis.
Archer TP; Moran GW; Ghosh S
Immunotherapy; 2016 May; 8(5):495-502. PubMed ID: 27140405
[TBL] [Abstract][Full Text] [Related]
19. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis.
Curtis JR; Xie F; Yun H; Bernatsky S; Winthrop KL
Ann Rheum Dis; 2016 Oct; 75(10):1843-7. PubMed ID: 27113415
[TBL] [Abstract][Full Text] [Related]
20. Tofacitinib: A Review in Rheumatoid Arthritis.
Dhillon S
Drugs; 2017 Dec; 77(18):1987-2001. PubMed ID: 29139090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
